{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone&page=24", "query": { "intervention": "Prednisone", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 1199, "total_pages": 120, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T19:26:12.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00815919", "title": "Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2008-12", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2015-07-22", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00815919" }, { "nct_id": "NCT01359592", "title": "S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "R-CHOP regimen", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "selective external radiation therapy", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2011-09", "completion_date": "2023-12", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 240, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Aurora, Colorado + 153 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01359592" }, { "nct_id": "NCT02927834", "title": "Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sinusitis" ], "interventions": [ { "name": "6 day Prednisone", "type": "DRUG" }, { "name": "Augmentin", "type": "DRUG" }, { "name": "21 day Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2015-08", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02927834" }, { "nct_id": "NCT00623766", "title": "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Corticosteroid: Betamethasone", "type": "DRUG" }, { "name": "Corticosteroid: Dexamethasone", "type": "DRUG" }, { "name": "Corticosteroid: Fludrocortisone", "type": "DRUG" }, { "name": "Corticosteroid: Hydrocortisone", "type": "DRUG" }, { "name": "Corticosteroid: Meprednisone", "type": "DRUG" }, { "name": "Corticosteroid: Methylprednisolone", "type": "DRUG" }, { "name": "Corticosteroid: Prednisolone", "type": "DRUG" }, { "name": "Corticosteroid: Prednisone", "type": "DRUG" }, { "name": "Corticosteroid: Triamcinolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 99, "start_date": "2008-07", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623766" }, { "nct_id": "NCT01858922", "title": "Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "ABVE-PC", "type": "DRUG" }, { "name": "DECA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2012-12-19", "completion_date": "2019-08-12", "has_results": false, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01858922" }, { "nct_id": "NCT00911859", "title": "A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Siltuximab11 mg/kg", "type": "DRUG" }, { "name": "Siltuximab 8.3 mg/kg or 11 mg/kg", "type": "DRUG" }, { "name": "Velcade (bortezomib)", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2009-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2014-11-18", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00911859" }, { "nct_id": "NCT00473746", "title": "Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "prednisone/prednisolone or dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 66, "start_date": "2006-06", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 3, "location_summary": "San Francisco, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00473746" }, { "nct_id": "NCT00459186", "title": "The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic, Androgen Independent Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 19, "start_date": "2005-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2016-05-16", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Portland, Oregon", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459186" }, { "nct_id": "NCT02619552", "title": "Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Crohn's Disease", "IBD" ], "interventions": [ { "name": "Anti-TNF", "type": "DRUG" }, { "name": "Steroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2011-08", "completion_date": "2019-07-01", "has_results": false, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Hershey, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02619552" }, { "nct_id": "NCT01685268", "title": "A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "AT13387", "type": "DRUG" }, { "name": "abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 49, "start_date": "2012-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-10-27T19:26:12.091Z", "location_count": 20, "location_summary": "Los Angeles, California • Stanford, California • Fort Lauderdale, Florida + 16 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01685268" } ] }